When drug development and the immune system collide we get CAR-T, checkpoint inhibitors, oncolytic vaccines, monoclonal antibodies and more. These fields have produced many therapies and garnered a ...
Complement activation is common in patients with systemic lupus erythematosus (SLE), resulting in hypocomplementemia and deposition of complement at sites of tissue damage. The availability of mice ...
It was called ‘complement’ because it aided the antibacterial activity of antibodies. However, it is now known that the complement system can be activated early in an infection without the presence of ...
Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
Study of lead program will provide proof-of-concept to enable further clinical development in severe autoimmune diseases; full cohort data available in 2H'23 DNTH103 is a next-generation monoclonal ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 96, No. 2 (Jan. 19, 1999), pp. 628-633 (6 pages) Decay-accelerating factor (DAF) is a glycosylphosphatidylinositol ...
“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502, our ...
The current coronavirus disease 2019 (COVID-19) pandemic, which is due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 5.5 million casualties to date. Despite ...
Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback